- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Therapeutic Areas
- Oncology
- Publications
- Programs
- Pipeline
- mTORC1/2 inhibitor Sapanisertib
- SYK Inhibitor Mivavotinib
- Preclinical Programs
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Therapeutic Areas
Publications and Presentations
Check out our publications and poster presentations.
April 2014
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancerMolecular Cancer Therapeutics
April 2013
Anti-Tumor Activity of Novel, Potent and Orally-Bioavailable Glutaminase inhibitorAmerican Association of Cancer Research – 2013
Our Pipeline
We are focused on novel treatments for
cancer and other life-threatening diseases.